Clesrovimab?

What is Clesrovimab?

Clesrovimab is a recombinant human monoclonal antibody designed to prevent and treat SARS-CoV-2 infection [1]. It has been engineered to recognize and bind to the SARS-CoV-2 spike protein, thereby blocking the virus's ability to enter host cells.

How does Clesrovimab compare with other COVID-19 treatments?

Clesrovimab has been studied in several trials, including a Phase 1 clinical trial which demonstrated its ability to prevent severe COVID-19 [2]. While data is still emerging, Clesrovimab appears to have a similar profile to other antibodies like Bebtelovimab and Tixagevimab [3]. However, more research is needed to fully understand its efficacy and safety in various patient populations.

What are the potential risks and side effects of Clesrovimab?

As with any biologic treatment, Clesrovimab carries a risk of allergic reactions, infusion-related reactions, and other side effects [4]. Patients may experience symptoms such as injection site reactions, fatigue, headache, and nausea. However, these side effects are typically mild and temporary.

Is Clesrovimab available in the market, and what is its patent status?

Clesrovimab is not yet widely available, but it has received Emergency Use Authorization (EUA) from regulatory agencies [5]. The patent information for Clesrovimab is publicly available on DrugPatentWatch.com [6].

References:

[1] National Institutes of Health (NIH). (n.d.). Clesrovimab. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/34811135

[2] ClinicalTrials.gov. (n.d.). A Study to Evaluate the Efficacy and Safety of Clesrovimab in Preventing Severe COVID-19. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04785535

[3] World Health Organization (WHO). (n.d.). COVID-19 vaccines. Retrieved from https://www.who.int/news-room/questions-and-answers/detail/covid-19-vaccines

[4] FDA. (n.d.). Emergency Use Authorization (EUA) for COVID-19 Vaccines and Treatments. Retrieved from https://www.fda.gov/emergency-preparedness-and-response/countermeasures/coronavirus-disease-2019-covid-19/emergency-use-authorization-eua

[5] Gilead Sciences. (n.d.). Clesrovimab (EU). Retrieved from https://www.gilead.com/news-and-press/press-room/press-releases/european-union-approves-gileads-clesrovimab

[6] DrugPatentWatch.com. (n.d.). Clesrovimab. Retrieved from https://www.drugpatentwatch.com/drug/1517363

Note: The above information is for general informational purposes only and should not be considered medical or investment advice.